The vaccinia virus fusion inhibitor proteins SPI-3 (K2) and HA (A56) expressed by infected cells reduce the entry of superinfecting virus.
about
Use of Reporter Genes in the Generation of Vaccinia Virus-Derived VectorsPoxvirus cell entry: how many proteins does it take?Modulation of NKp30- and NKp46-mediated natural killer cell responses by poxviral hemagglutininDisulfide bond formation at the C termini of vaccinia virus A26 and A27 proteins does not require viral redox enzymes and suppresses glycosaminoglycan-mediated cell fusion.Repulsion of superinfecting virions: a mechanism for rapid virus spread.The neutralizing antibody response to the vaccinia virus A28 protein is specifically enhanced by its association with the H2 proteinA novel mode of poxvirus superinfection exclusion that prevents fusion of the lipid bilayers of viral and cellular membranesPoxvirus complement control proteins are expressed on the cell surface through an intermolecular disulfide bridge with the viral A56 protein.Smallpox vaccines: targets of protective immunity.Evolution of and evolutionary relationships between extant vaccinia virus strainsVaccinia mature virus fusion regulator A26 protein binds to A16 and G9 proteins of the viral entry fusion complex and dissociates from mature virions at low pHThe vaccinia virus A56 protein: a multifunctional transmembrane glycoprotein that anchors two secreted viral proteinsReciprocal functional pseudotyping of HIV-1 and HTLV-1 viral genomes by the heterologous counterpart envelope proteins.Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion.Induction of cell-cell fusion by ectromelia virus is not inhibited by its fusion inhibitory complex.Characterization of a newly identified 35-amino-acid component of the vaccinia virus entry/fusion complex conserved in all chordopoxviruses.Poxvirus proteomics and virus-host protein interactions.Surf and turf: mechanism of enhanced virus spread during poxvirus infection.The E6 protein from vaccinia virus is required for the formation of immature virionsMyxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells.A comparative review of viral entry and attachment during large and giant dsDNA virus infections.
P2860
Q26746915-982CE52E-118A-460D-B7EF-94109F4CD437Q27002455-A0058882-19F7-4686-BC60-049787579BD7Q28476707-B0193A3B-92C4-47B5-A49A-8138FFDB0B0CQ30488301-C63B03F5-3CF1-4D7F-9B30-D8CB7CBECEFCQ30594313-01549A28-7D0C-4267-A42D-4C12EDFC81A5Q34039477-6631B2C8-1A34-4555-A39D-27CFE5BA88CEQ34059600-759BC993-902C-41BC-8F7D-D477451CE192Q34190609-A525B00E-F9D1-4B8A-930E-1CD14D01DA00Q34780607-1D6336AF-0489-47C7-8C10-5BA415C26799Q34991481-9F7A5D5E-D2FF-44D7-AB7A-90117074F1C0Q35826881-36968313-6C05-4994-92BA-9A3F9B592CCCQ35963805-5C1158D8-8366-4950-862C-98797C80F787Q37058590-11EF0491-EC99-4F92-9CF4-276527468561Q37099872-1918CDB8-739B-4129-891A-BF7337E563BCQ37384933-F7BB9A15-CC8C-402A-9059-84F430B0418CQ37452527-4342BCB6-C751-438D-876E-E4EE33DBC6BBQ37640977-BEA1CBEA-B79F-4791-B395-5F7B1619684AQ38632862-4E50F295-52E2-4F00-8C6B-EC9B9560BB69Q39338820-F8CB2123-4026-4B23-821C-B9815EDAEB58Q39723487-6CEB688B-F337-488A-8C18-54FDA88EDD36Q40060063-FD8039D6-736C-4315-8646-3156B1B98B37
P2860
The vaccinia virus fusion inhibitor proteins SPI-3 (K2) and HA (A56) expressed by infected cells reduce the entry of superinfecting virus.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
The vaccinia virus fusion inhi ...... entry of superinfecting virus.
@en
The vaccinia virus fusion inhibitor proteins SPI-3
@nl
type
label
The vaccinia virus fusion inhi ...... entry of superinfecting virus.
@en
The vaccinia virus fusion inhibitor proteins SPI-3
@nl
prefLabel
The vaccinia virus fusion inhi ...... entry of superinfecting virus.
@en
The vaccinia virus fusion inhibitor proteins SPI-3
@nl
P2860
P1433
P1476
The vaccinia virus fusion inhi ...... entry of superinfecting virus.
@en
P2093
Peter C Turner
Richard W Moyer
P2860
P304
P356
10.1016/J.VIROL.2008.07.020
P407
P577
2008-08-28T00:00:00Z